Src mediates acquired resistance to ALK inhibitor in ALK-rearranged non-small cell lung cancers

被引：0
|
作者：
Yoshida, Ryohei
Okumura, Shunsuke
Sasaki, Takaaki
Osaki, Yoshinobu
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2121
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients
    Miyazaki, Kunihiko
    Sato, Shinya
    Kodama, Takahide
    Numata, Takeshi
    Endo, Takeo
    Yamamoto, Yusuke
    Shimizu, Kei
    Yamada, Hideyasu
    Hayashihara, Kenji
    Okauchi, Shinichiro
    Satoh, Hiroaki
    Yamada, Yutaka
    Tamura, Tomohiro
    Saito, Kazuto
    Kikuchi, Norihiro
    Kurishima, Koichi
    Ishikawa, Hiroichi
    Watanabe, Hiroko
    Shiozawa, Toshihiro
    Hizawa, Nobuyuki
    Funayama, Yasunori
    Hayashi, Shigen
    Nakamura, Hiroyuki
    Yamashita, Takaaki
    IN VIVO, 2020, 34 (04): : 2001 - 2007
  • [32] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Lau, Yvonne Y.
    Goldwasser, Meredith
    Boral, Anthony L.
    Engelman, Jeffrey A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (13): : 1189 - 1197
  • [33] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shen, Liang
    Ji, Hong-Fang
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (26): : 2537 - 2537
  • [34] Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
    Fabrizio Tabbò
    Francesco Passiglia
    Silvia Novello
    Current Oncology Reports, 2021, 23
  • [35] Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
    Tabbo, Fabrizio
    Passiglia, Francesco
    Novello, Silvia
    CURRENT ONCOLOGY REPORTS, 2021, 23 (01)
  • [36] Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy
    Tsui, David Chun Cheong
    Aisner, Dara
    Nijmeh, Hala
    Bao, Liming
    Menter, Alexander
    Camidge, D. Ross
    CLINICAL LUNG CANCER, 2022, 23 (02) : E99 - E103
  • [37] EGFR activation elicited adaptive resistance to lorlatinib in ALK-rearranged non-small cell lung cancer cells
    Katayama, Yuki
    Yamada, Tadaaki
    Tanimura, Keiko
    Morimoto, Kenji
    Yoneda, Kazue
    Horinaka, Mano
    Sakai, Toshiyuki
    Ozasa, Hiroaki
    Takayama, Koichi
    ANNALS OF ONCOLOGY, 2023, 34 : S1421 - S1421
  • [38] A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer
    Esfahani, Khashayar
    Agulnik, Jason Scott
    Cohen, Victor
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [39] Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer
    Santarpia, Mariacarmela
    Altavilla, Giuseppe
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (03) : 255 - 268
  • [40] Native and Rearranged ALK Copy Number and Rearranged Cell Count in Non-Small Cell Lung Cancer Implications for ALK Inhibitor Therapy
    Camidge, D. Ross
    Skokan, Margaret
    Kiatsimkul, Porntip
    Helfrich, Barbara
    Lu, Xian
    Baron, Anna E.
    Schulte, Nathan
    Maxson, DeLee
    Aisner, Dara L.
    Franklin, Wilbur A.
    Doebele, Robert C.
    Varella-Garcia, Marileila
    CANCER, 2013, 119 (22) : 3968 - 3975
12345